KPV

KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (α-MSH). It seems to carry much of α-MSH's anti-inflammatory activity without strongly affecting pigmentation. In cell and animal models it dampens pro-inflammatory signaling (notably NF-κB) inside immune and epithelial cells, and it can be taken up directly by intestinal cells, which is why gut inflammation is a major research focus.

KPV's anti-inflammatory effects are reproducible in vitro and in rodent models of colitis, and its small size and oral/topical absorption make it pharmacologically interesting. But the evidence stops at the preclinical stage: there are no published human RCTs establishing benefit for inflammatory bowel disease, skin conditions, or recovery. Treat the human case as plausible-but-unproven.

• Reduced colonic inflammation in animal models of colitis
• Anti-inflammatory effects on immune and epithelial cells in vitro
• Wound-healing and antimicrobial activity in skin models
• Direct uptake by intestinal cells, supporting oral interest

• No published human RCTs — clinical benefit is unproven
• Long-term human safety unknown
• Research-use-only sourcing; purity and dose vary
• Mechanistic overlap with a hormone pathway whose systemic effects are not fully characterized for this fragment

Research compound. Sold "for research use only" — not approved for human consumption.

Goals studied: Gut healing, Skin anti-aging

What is KPV used for in research?

Mostly inflammation — particularly gut inflammation like colitis — and some skin and wound applications, all at the preclinical stage.

Can KPV be taken orally?

In animal studies it is absorbed by intestinal cells, which is part of its appeal, but there are no human trials establishing an effective or safe oral dose.

1. [1]
   PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation

   Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D · Gastroenterology · 2008 · PMID 18061177 · model: animal

   Étude sur cellules et modèles murins de colite montrant que le KPV entre dans les cellules via PepT1 et atténue l'inflammation médiée par NF-κB.

2. [2]
   Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease

   Kannengiesser K, Maaser C, Heidemann J, et al. · Inflammatory Bowel Diseases · 2008 · PMID 18092346 · model: animal

   Étude sur modèles murins de MICI rapportant une réduction des lésions coliques et des cytokines inflammatoires sous KPV.